Veterinary Anti-Infective Market
Veterinary Anti-Infective Market Study by Antimicrobial Agents, Antiviral Agents, Antifungal Agents, and Antiparasitic Agents for Livestock and Companion Animals from 2024 to 2034
Analysis of Veterinary Anti-Infective Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Veterinary Anti-Infective Market Outlook (2024 to 2034)
Revenue from the global veterinary anti-infective market size is estimated to reach US$ 5.03 billion in 2024. The market is analyzed to climb to a value of US$ 7.47 billion by the end of 2034, expanding at a CAGR of 4%.
Anti-infectives are products that help prevent the spread or transmission of diseases. Moreover, veterinary anti-infectives are instrumental in halting or treating the transmission of infectious diseases between humans and animals.
Use of anti-infectives has increased in recent years due to the rising demand for animal products such as meat, milk, and other foods, as well as diseases associated with these animals. The natural transmission of zoonotic and foodborne illnesses from animals to humans occurs when a human comes into contact with an infected animal or person, consumes contaminated food or water, or is exposed to the pathogen during preparation or processing.
An antimicrobial drug's ability to inhibit or kill bacteria is determined by its mechanism of action and the concentration at the infection site. A drug's antibacterial activity is chemically altered or decreased, and its excretion is aided, by the liver, kidneys, and other organs that quickly absorb it through the bloodstream.
Key Market Growth Drivers
- Focus on the prevention and treatment of fatal animal diseases are important driving demand for veterinary antibiotics. Several factors, including the surge in foodborne and zoonotic diseases, the increasing popularity of pets, and the expansion of research and development in animal healthcare, contribute to the expanding size of the veterinary anti-infective market.
- The rising trend of pet ownership is projected to contribute to the expansion of the veterinary anti-infective market size. More and more individuals, particularly young people, are embracing pets as integral members of their families. Some adopt pets to alleviate loneliness and benefit from their companionship and loyalty.
- Increasing livestock production is a key driver for market growth. These medications play a crucial role in treating animal infections and promoting their overall health and well-being. They are indispensable for both preventing and managing illnesses within the animal population.
- Escalation of foodborne illnesses stands out as a primary catalyst for the expansion of the anti-infective drug market. Animals serve as significant sources of infectious diseases that can be transmitted to humans. Controlling these diseases is paramount for public health officials due to the threats they pose to human well-being.
- The growing trend of pet adoption, coupled with mounting concerns about pet health and the prevalence of bacterial infections, particularly among dogs, is poised to drive veterinary anti-infective market growth.
| Report Attribute | Detail |
|---|---|
| Veterinary Anti-Infective Market Size (2024E) | US$ 5.03 Billion |
| Forecasted Market Value (2034F) | US$ 7.47 Billion |
| Global Market Growth Rate (2024 to 2034) | 4% CAGR |
| Latin America Market Share (2024E) | 13% |
| North America Market Share (2024E) | 34.4% |
| Revenue from Veterinary Clinics (2024E) | US$ 1.9 Billion |
| Key Companies Profiled | Neogen Corporation; Phibro Animal Health Corporation; Sanofi (Merial Animal Health); Vetoquinol S.A.; Virbac S.A.; Zoetis, Inc.; Boehringer Ingelheim GmbH; Ceva Santé Animale; Indian Immunologicals Limited; Intas Pharmaceuticals Limited; Norbrook Laboratories Limited; Ashish Life Science Private; Zydus Animal Health Limited. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is There Steadily Growing Demand for Veterinary Care and Anti-Infectives?
“Increasing Pet Humanization Driving Focus on Their Healthcare and Well-Being”
Global surge in pet adoption, notably of dogs and cats, is contributing to concerns regarding the health and hygiene of these animals, thereby driving sales of anti-infectives. Growing demand for pet companionship and the corresponding need for veterinary care are key veterinary anti-infective market trends. Dogs and cats, in particular, are susceptible to bacterial diseases like the plague, among others.
Animals can potentially transmit diseases to humans, underscoring the importance of increased pet vaccination rates to control and treat these ailments. Ongoing research aims to develop novel and more efficacious medications, with human trials underway to assess their effectiveness.
What Challenges are Manufacturers of Veterinary Anti-Infectives Facing?
“Rising Antimicrobial Resistance and Availability of Generic Alternatives”
Veterinary anti-infective manufacturers are encountering significant challenges due to rising antimicrobial resistance. To address concerns about antimicrobial resistance (AMR), regulatory authorities are increasingly focused on ensuring the responsible use of antibiotics and other anti-infective agents in animals. The presence of generic alternatives to branded veterinary anti-infectives presents a competitive hurdle for market participants, as cost-conscious consumers opt for cheaper options. Maintaining market share requires differentiation through superior product quality and efficacy.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America is expected to occupy a revenue share of 34.4% in 2024. The growth of this regional market is projected to be fueled by the existence of cutting-edge animal healthcare programs and increased public awareness of animal health during the forecast period.
- To address the issues affecting the animal health industry, the North American Pet Health Insurance Association is focusing on raising awareness of pet health insurance coverage and creating and investigating partnerships.
Need for quick and efficient treatment options is also being driven by the increased prevalence of diseases in pets and livestock, which is expected to fuel demand for veterinary anti-infectives in the region.
- The Food and Agriculture Organization (FAO) estimates that there are more than 1.4 billion cattle worldwide, with a sizable portion of them living in nations like China, Brazil, and India.
What’s Driving Veterinary Anti-Infective Sales in the United States?
“Extensive Use of Veterinary Anti-Infectives to Preserve Safety of Animal Products”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 1.17 Billion |
| Growth Rate (2024 to 2034) | 3.5% CAGR |
| Projected Value (2034F) | US$ 1.65 Billion |
The United States is set to hold 67.8% of the veterinary anti-infective market share in North America in 2024. Growing demand for anti-infectives for companion animals is driven by the rising number of pet owners in the United States. Veterinarian prescriptions for both preventive and therapeutic purposes are being used more frequently as a result of growing pet owners' concerns about their animals' health.
Due to the high demand for premium meat in the United States, livestock are effectively prevented from contracting diseases and treated when they do. Ensuring the health of farm animals becomes increasingly important as consumers are becoming more health-conscious. Veterinary anti-infectives are essential to preserving food safety and animal health.
How is the Market for Veterinary Anti-Infectives Evolving in Brazil?
“Large Cattle Population Prompting Increased Control Over Veterinary Anti-infectives”
| Attribute | Brazil |
|---|---|
| Market Value (2024E) | US$ 319 Million |
| Growth Rate (2024 to 2034) | 4.5% CAGR |
| Projected Value (2034F) | US$ 496 Million |
Brazil is a lucrative market for producers of anti-infectives due to its large cattle population. Brazil has been enforcing stricter regulations on the use of antibiotics and other anti-infectives in veterinary medicine. Concerns regarding antimicrobial resistance and its effects on the health of humans and animals have prompted some of these measures.
Consequently, there is more oversight and control over veterinary anti-infectives, such as limitations on specific antibiotic classes or the need for prescriptions to use them. Knowledge of the significance of appropriate antibiotic use and the effects of antimicrobial resistance is expanding among veterinarians, pet owners, and livestock producers. As a result, there is now more focus on preventive measures that reduce the need for anti-infective medications, such as vaccination, biosecurity, and good hygiene practices.
Category-wise Insights
The global market is divided into two main segments: antiviral agents and antimicrobial agents. In terms of species, it is classified into livestock animals, and companion animals, of which the former is set to hold a market share of 67.6% in 2024. Anti-infectives are administered through oral, parenteral, and topical modes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, and other channels.
Why Do Antimicrobial Agents Account for a Significant Market Share?
“Wide Usage of Antimicrobial Agents Driven by Their Proven Efficacy”
| Attribute | Antimicrobial Agents |
|---|---|
| Segment Value (2024E) | US$ 2.73 Billion |
| Growth Rate (2024 to 2034) | 3.9% CAGR |
| Projected Value (2034F) | US$ 4.01 Billion |
In the drug class segment, the antimicrobial agents sub-segment is projected to account for a 50% market share during the forecast period. Antimicrobial agents that find widespread usage include tetracyclines, cephalosporins, and Penicillin. In terms of revenue, the antimicrobial agents segment is leading the global veterinary anti-infective market, and this pattern is forecasted to hold steady throughout the forecast period.
How are Veterinary Hospitals and Clinics Contributing to Market Growth?
“Hospitals and Clinics Ensuring Compliance with Regulations for Veterinary Anti-infective Use”
| Attribute | Veterinary Clinics |
|---|---|
| Segment Value (2024E) | US$ 1.9 Billion |
| Growth Rate (2024 to 2034) | 4.1% CAGR |
| Projected Value (2034F) | US$ 2.85 Billion |
Veterinary clinics and hospitals are poised to account for 70% market share in 2024. Stricter regulations being put in place to prevent animal diseases and growing awareness of veterinary healthcare are driving demand for veterinary anti-infectives in hospitals and clinics. Over the course of the forecast period, an increasing number of government initiatives to promote veterinary services in hospitals and clinics are projected to fuel market growth.
Guidelines for veterinary health are being released by government organizations, which is fueling market expansion.
- As an illustration, the WTO framework's OIE International Standards published guidelines to enhance veterinary care and advance global animal health.
By rejecting goods that do not meet set standards, these actions can help with the early detection, control, and reporting of pathogenic agents and stop their spread.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the veterinary anti-infective market have enormous opportunities to invest in the global veterinary anti-infective market through biologics and specialty care. Focus on research aimed at improving the efficacy of veterinary anti-infectives is driving market growth.
- The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched in November 2022 by the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), also known as the Quadripartite. In addition to ensuring that the effects of antimicrobial resistance are addressed globally, this project aims to draw attention to the threat that antimicrobial resistance (AMR) poses to people, animals, plants, ecosystems, and livelihoods.
- The United States-based pharmaceutical company Elanco Animal Health Incorporated, which produces medications and vaccines for pets and livestock, introduced Increxxa, the recently approved medication for livestock respiratory disease, in February 2021.
- Tulathromycin, the main ingredient in Increxxa, is injected into cattle to target the infection site in the lungs quickly. This fast action and long half-life give the cattle more time to build up a robust defense. The active component of Increxxa, tulathromycin, helps lessen the harmful effects of bovine respiratory disease; this product is intended for veterinary use.
Fact.MR provides detailed information about the price points of key providers of veterinary anti-infectives positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.
Segmentation of Veterinary Anti-Infective Market Research
-
By Species :
- Livestock Animals
- Companion Animals
-
By Drug Class :
- Antimicrobial Agents
- Antiviral Agents
- Antifungal Agents
- Antiparasitic Agents
-
By Mode of Administration :
- Oral
- Parenteral
- Topical
-
By Distribution Channel :
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Species
- 6.2. Drug Class
- 6.3. Mode of Administration
- 6.4. Distribution Channel
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Species
- 7.1. Livestock Animals
- 7.2. Companion Animals
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
- 8.1. Antimicrobial Agents
- 8.2. Antiviral Agents
- 8.3. Antifungal Agents
- 8.4. Antiparasitic Agents
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Mode of Administration
- 9.1. Oral
- 9.2. Parenteral
- 9.3. Topical
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 10.1. Veterinary Hospitals
- 10.2. Veterinary Clinics
- 10.3. Pharmacies
- 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. East Asia
- 11.6. South Asia & Pacific
- 11.7. Middle East & Africa
- 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 19. Sales Forecast 2024 to 2034 by Species, Drug Class, Mode of Administration, Distribution Channel, and Region for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Neogen Corporation
- 21.2. Phibro Animal Health Corporation
- 21.3. Sanofi (Merial Animal Health)
- 21.4. Vetoquinol S.A.
- 21.5. Virbac S.A.
- 21.6. Zoetis, Inc.
- 21.7. Boehringer Ingelheim GmbH
- 21.8. Ceva Santé Animale
- 21.9. Indian Immunologicals Limited
- 21.10. Intas Pharmaceuticals Limited
- 21.11. Norbrook Laboratories Limited
- 21.12. Ashish Life Science Private
- 21.13. Zydus Animal Health Limited
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 25: North America Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 26: North America Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 28: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 29: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 30: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 37: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 38: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 40: Latin America Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 41: Latin America Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 42: Latin America Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 43: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 44: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 45: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: Western Europe Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 50: Western Europe Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 51: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 52: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 53: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 54: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 55: Western Europe Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 56: Western Europe Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 57: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 58: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: Eastern Europe Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 65: Eastern Europe Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 66: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 67: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 68: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 69: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 70: Eastern Europe Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 71: Eastern Europe Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 72: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 73: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 74: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 75: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 76: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 77: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 78: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 79: East Asia Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 80: East Asia Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 81: East Asia Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 82: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 83: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 84: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 85: East Asia Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 86: East Asia Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 87: East Asia Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 88: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 89: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 90: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 91: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 92: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 93: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 94: South Asia & Pacific Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 95: South Asia & Pacific Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 96: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 97: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 98: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 99: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 100: South Asia & Pacific Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 101: South Asia & Pacific Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 102: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 103: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 104: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 105: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 106: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 107: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 108: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 109: MEA Market Value (US$ Mn) Analysis, by Species, 2019 to 2023
Table 110: MEA Market Value (US$ Mn) Analysis, by Species, 2024 to 2034
Table 111: MEA Market Value (US$ Mn) Opportunity Analysis, by Species, 2024 to 2034
Table 112: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 113: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 114: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 115: MEA Market Value (US$ Mn) Analysis, by Mode of Administration, 2019 to 2023
Table 116: MEA Market Value (US$ Mn) Analysis, by Mode of Administration, 2024 to 2034
Table 117: MEA Market Value (US$ Mn) Opportunity Analysis, by Mode of Administration, 2024 to 2034
Table 118: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 119: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 120: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Species, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Species, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 17: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 18: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 19: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 20: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 21: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 22: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 23: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 24: North America Market Share Analysis by Country, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Species, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Species, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 33: North America Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 34: North America Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 36: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 37: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 38: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 39: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 40: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 41: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 42: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 43: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Species, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Species, 2024 to 2034
Figure 49: Latin America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 50: Latin America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 52: Latin America Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 53: Latin America Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 54: Latin America Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 55: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 56: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 57: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 58: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 59: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 60: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 61: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 62: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Western Europe Market Share and BPS Analysis by Species, 2024 & 2034
Figure 66: Western Europe Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 67: Western Europe Market Attractiveness Analysis by Species, 2024 to 2034
Figure 68: Western Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 69: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 70: Western Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 71: Western Europe Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 72: Western Europe Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 73: Western Europe Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 74: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 75: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 76: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 77: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 78: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 79: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 80: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 81: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 82: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 83: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 84: Eastern Europe Market Share and BPS Analysis by Species, 2024 & 2034
Figure 85: Eastern Europe Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 86: Eastern Europe Market Attractiveness Analysis by Species, 2024 to 2034
Figure 87: Eastern Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 88: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 89: Eastern Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 90: Eastern Europe Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 91: Eastern Europe Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 92: Eastern Europe Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 93: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 94: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 95: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 96: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 97: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 98: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 99: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 100: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 101: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 102: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 103: East Asia Market Share and BPS Analysis by Species, 2024 & 2034
Figure 104: East Asia Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 105: East Asia Market Attractiveness Analysis by Species, 2024 to 2034
Figure 106: East Asia Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 107: East Asia Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 108: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 109: East Asia Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 110: East Asia Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 111: East Asia Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 112: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 113: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 115: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 116: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 117: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 118: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 119: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 120: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 121: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 122: South Asia & Pacific Market Share and BPS Analysis by Species, 2024 & 2034
Figure 123: South Asia & Pacific Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 124: South Asia & Pacific Market Attractiveness Analysis by Species, 2024 to 2034
Figure 125: South Asia & Pacific Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 126: South Asia & Pacific Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 127: South Asia & Pacific Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 128: South Asia & Pacific Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 129: South Asia & Pacific Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 130: South Asia & Pacific Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 131: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 132: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 133: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 134: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 135: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 136: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 137: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 138: MEA Market Share Analysis by Country, 2024 & 2034
Figure 139: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 140: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 141: MEA Market Share and BPS Analysis by Species, 2024 & 2034
Figure 142: MEA Market Y-o-Y Growth Projections by Species, 2024 to 2034
Figure 143: MEA Market Attractiveness Analysis by Species, 2024 to 2034
Figure 144: MEA Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 145: MEA Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 146: MEA Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 147: MEA Market Share and BPS Analysis by Mode of Administration, 2024 & 2034
Figure 148: MEA Market Y-o-Y Growth Projections by Mode of Administration, 2024 to 2034
Figure 149: MEA Market Attractiveness Analysis by Mode of Administration, 2024 to 2034
Figure 150: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 151: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 152: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the veterinary anti-infective market?
The global market for veterinary anti-infectives is estimated at US$ 5.03 billion in 2024.
What are the sales projections for veterinary anti-infectives over the decade?
The global market is forecasted to expand at 4% CAGR and reach US$ 7.47 billion by the end of 2034.
Which country has a significant market for veterinary anti-infectives?
Revenue from veterinary anti-infectives in the United States is projected to reach US$ 1.17 billion in 2024.
What are the projections for the market in Brazil?
Brazil is estimated to reach a market value of US$ 319 million in 2024.
Which distribution channel accounts for higher sales of veterinary anti-infectives?
Revenue from veterinary anti-infective clinics is expected to reach US$ 1.9 billion in 2024.
What is the share of Canada in the North American market?
Canada accounts for a market share of 21.2% in North America in 2024.
Who are the leaders in the business of veterinary anti-infectives?
Ceva Santé Animale, Indian Immunologicals Limited, Intas Pharmaceuticals Limited, Norbrook Laboratories Limited, and Ashish Life Science Private are key market players.
Veterinary Anti-Infective Market